Table 2.

Prognostic factors for overall survival (OS) in colorectal cancer.

Prognostic factors	n	5-year OS rate (%)	Univariate P value	Multivariate HR (95% CI)	P value
Age at primary surgery, < 65/ ≥ 65	44/22	54.6/60.8	0.7742
Sex, Male/Female	44/22	53.8/68.2	0.7217
Site of primary tumor, Colon/Rectum	40/26	74.7/34.6	0.0022	0.30 (0.129–0.647)	0.0019
Site of primary tumor, Right/Left	19/47	78.6/51.1	0.0486	0.93 (0.339–2.541)	0.8864
CEA < 5/ ≥ 5	18/48	65.5/56.3	0.1631
CA19-9 < 37/ ≥ 37	43/23	64.5/47.8	0.2476
Degree of differentiation, tub, pap/por, muc	62/4	57.6/75.0	0.9649
ly, 0–1/2–3	55/11	56.4/71.6	0.9228
v, 0–1/2–3	31/35	71.0/47.5	0.1033
T stage (8th edition), 1–3/4	37/29	64.9/50.6	0.2924
Lymph node metastasis, − / +	27/39	69.7/51.3	0.0112	0.43 (0.195–0.909)	0.0265
KRAS mutation, Wild/Mutant	11/18	55.6/45.5	0.6377
Adjuvant chemotherapy after primary surgery, − / +	56/10	60.2/50.0	0.3630
Timing of liver metastasis, Synchronous/metachronous	27/39	53.9/65.8	0.2591
Metastasis other than liver, − / +	54/12	62.5/41.7	0.1181
Number of liver metastasis, Solitary/Multiple	23/43	69.1/53.5	0.1929
Size of largest tumor (cm), < 5/ ≥ 5	53/13	65.6/46.2	0.3057
Hepatectomy, Minor/Major	56/10	62.6/40.0	0.0687
Surgical margin, R0/R1,R2	35/31	67.9/48.4	0.0287	0.49 (0.241–0.972)	0.0410
H factor, H1/H2-H3	43/23	71.6/34.8	0.0171	0.70 (0.327–1.548)	0.3713
Expression of Smurf 2 in primary tumor, High/Low	31/35	71.0/47.6	0.0265	0.47 (0.232–0.957)	0.0370

CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19–9; KRAS, Kirsten rat sarcoma viral oncogene.